Product
GLM101
1 clinical trial
1 indication
Indication
Pmm2-CDGClinical trial
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent, and Pediatric Participants With PMM2-CDGStatus: Recruiting, Estimated PCD: 2025-04-01